INTRODUCTION

Extensive T-cell depletion (TCD) associated with megadoses of mobilized selected CD34
+ cells has been successfully used to promote engraftment of hematopoietic stem cells from haploidentical donors, while minimizing the risks associated with acute and chronic GvHD. 1, 2 However, TCD severely impairs post transplant immune recovery and necessarily reduces the GvL activity mediated by alloreactive T lymphocytes. In a retrospective survey promoted by the Acute Leukemia Working Party of EBMT, a high incidence of non-relapse mortality (NRM) and leukemia relapse was confirmed on a multicenter scale in adults receiving haploidentical (haplo) SCT (HSCT) for acute leukemia. 3 At the San Raffaele Scientific Institute, we approached this major unmet medical need by implementing two separate platforms of haplo-HSCT: a T cell add-back strategy with suicide gene modified donor T cells to promote immune reconstitution and, more recently, an unmanipulated peripheral-blood graft platform more dedicated to patients undergoing haplo-HSCT with leukemia in advanced status at time of transplant. In this review, a 15-year clinical experience is presented.
T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC SCT: AN IDEAL PLATFORM FOR CELLULAR THERAPY AND CELL-BASED GENE THERAPY
Extensive efforts have been made to modulate, abrogate or control T cell-mediated alloreactivity, with the purpose of reducing the risk of GvHD while preserving post transplant immune reconstitution and anti-tumor activity.
The TCD haploidentical HSCT protocols represent ideal platforms to develop and validate innovative adoptive immunotherapy approaches: the rapid and robust hematopoietic reconstitution, associated with a profound lymphodepletion and with the absence of immunosuppressive drugs, represent favorable grounds for the engraftment and expansion of adoptively transferred T cells. This clinical soil and the imperative medical need have been the basis for a wide range of cellular therapy approaches, characterized by variable levels of graft manipulation and complexity, varying from the infusion of purified T-cell subpopulations to the administration of genetically modified donor T cells. 4 Infusion of donor lymphocytes depleted of the alloreactive potential GvHD incidence and severity is directly linked to the alloreactive burden transferred to patients with the transplant or as add-back. Accordingly, several cellular therapy approaches have been designed and tested at the preclinical and clinical level, to reduce the alloreactive cargo associated with haplo-HSCT. One approach relies on ex vivo activation of donor T cells with host antigens, to selectively purge alloreactive lymphocytes, based on their activation status. In initial trials, several surface activation molecules, such as CD25, 5, 6 CD69, 7 CD95, 8 and CD137, 9 have been targeted by immunotoxins to negatively select activated T cells. More recently, photodepletion of alloreactive T cells has been obtained by exploiting the preferential accumulation of photoactive cytotoxic compounds by activated T cells. In the haploidentical setting, the photodynamic purging of activated alloreactive lymphocytes was successful in controlling the risk of GvHD (13% in 24 patients treated), but limited by a NRM at 2 years of 48%, suggesting that the overall quality of post transplant immune reconstitution obtained through photodepletion is still suboptimal 10 in this transplantation context. In experimental models, alloreactivity appears to cluster with specific T-cell subsets such as CD8 or naïve T cells, or αβ T cells. 11 Accordingly, the infusion of donor T cells depleted of selected T subsets is currently tested in clinical trials. [12] [13] [14] Recently, Bertaina et al. 15 reported the infusion of a haploidentical graft ex vivo depleted of αβ T and B cells in 23 children affected by nonmalignant diseases. In the absence of post transplantation pharmacologic prophylaxis, acute grade I-II GvHD was observed in only three patients, while no chronic GvHD was reported. Cumulative incidence of TRM was 9.3% at a median follow-up of 18 months, suggesting that this approach is safe and effective when applied to non-malignant diseases.
15
SUICIDE GENE THERAPY TO PROMOTE IMMUNE RECONSTITUTION AND TAME GVHD By reducing the alloreactive burden transferred to transplanted patients, the above-mentioned approaches hinder a strong immunological force against residual cancer cells, represented by alloreactivity itself. Indeed, clinical observations indicate that GvHD and GvL often occur in the same patient with different kinetics 16, 17 suggesting similar, if not identical mechanisms underlying the two clinical events. We recently reported the genomic loss of mismatched HLA as a frequent mechanism of leukemia immune evasion after haploidentical HSCT, 18, 19 a direct confirmation of the clinical relevance of alloreactive T cells in controlling leukemia in this transplant setting.
In the 90', at the San Raffaele Scientific Institute, we hypothesized that gene transfer technologies, originally developed to treat genetic diseases, 20, 21 could be employed to separate in vivo the beneficial GvL from the detrimental GvHD, associated with alloreactive T cells.
The rational of suicide gene therapy lays on the assumption that an intact donor T-cell repertoire, inclusive of alloreactive specificities, is required to promote a wide and protective post transplant immune reconstitution. To this purpose, donor T cells are genetically modified by a retroviral vector to express a suicide gene and immune selected before infusion. Suicide gene expression confers the selective sensitivity to a prodrug. The HSV-derived thymidine kinase (TK) is the most extensively tested suicide gene in clinical trials. TK phosphorylates ganciclovir (GCV), thus converting the prodrug to its active form. Phosphorylated GCV acts as a guanosine tri-phosphate analog and inhibits DNA chain elongation. Thus, this system offers two levels of specificity in GvHD control: first, only transduced cells are endowed with the ability of converting the prodrug in the active form; second, only gene-modified T cells in active proliferation are sensitive to the active drug. GCV administration during GvHD treatment is therefore meant to eliminate proliferating alloreactive T cells, while sparing resting T lymphocytes.
We initially reported the use of donor T cells expressing TK (TK cells) to treat relapse and control GvHD in the context of HLAidentical hematopoietic SCT. 22 In this setting, GCV administration resulted in control of acute or chronic GVHD in all treated patients. In vivo expansion of TK cells was observed and directly correlated with clinical responses. 23 Based on these results, the TK concept was then translated to TCD haplo-HSCT. In this setting, the risk of GvHD is particularly high, due to the immunological disparity between donor and host, and the need for immune reconstitution is critical to avoid severe infectious complications and relapse.
In the TK007 multicenter phase I-II clinical trial, 57 adult patients were enrolled to receive a TCD-haplo-HSCT followed by escalating infusions of TK cells at monthly intervals, starting 1 month after TCD haplo-HSCT, in the absence of pharmacologic prophylaxis for GvHD. Primary aims of the TK007 study were to evaluate incidence and time to immune reconstitution, defined by the number of circulating CD3+ ⩾ 100/μL for two consecutive observations, incidence of GvHD and GvHD response to GCV. Fiftytwo patients received the HSCT after myeloablative conditioning and 30 patients received a total of 49 infusions of TK cells. Overall, TK cells engrafted in 23 (77%) of the 30 treated patients and resulted in rapid immune reconstitution with circulating CD3+ cells ⩾ 100 cells/μL at a median time of 77 days (95% CI, 68-87) from the date of HSCT, 31 days (95% CI, 21-44) from the date of TK cell infusion, in all patients. Conversely, patients who failed TK cell engraftment remained profoundly immunodeficient. The T-cell repertoire observed after infusion of TK cells progressively improved from oligoclonal to polyclonal in 1 year. The proportion of IFNγ-producing CMV-and EBV-specific lymphocytes normalized within 3 months post HSCT. GvHD occurred in 11 patients, and in all cases the TK/GCV machinery proved to be effective, leading to a rapid and complete resolution of all clinical symptoms. The follow-up of patients after GvHD treatment confirmed the selective activity of GCV only on transduced cells, thus indicating a direct implication of proliferating TK cells in GvHD. Interestingly, the incidence and severity of viral infections registered in patients treated with GCV was similar to that observed in untreated patients, confirming the selective GvHD control offered by the TK/ GCV machinery, which kills all cells responsible for GvHD sparing the antiviral effectors. The cumulative incidence of NRM was 17% at 5 years, for the 23 immune-reconstituted patients, with 4% (±4) because of infection. According to disease status at HSCT, the cumulative incidence of disease relapse or progression was 48% at 1 year for patients transplanted with active disease, and 23% at 5 years for those transplanted in remission. Of notice, although TK cell infusions appeared necessary and sufficient to promote a rapid immune recovery, the long-term immune reconstitution was preferentially composed of donor-derived T lymphocytes negative for the transgene. We recently showed that TK-negative T cells circulating in treated patients are enriched in recent thymic emigrants, suggesting thymic regeneration. 24 This process, not observed in control cohorts of patients, treated with unmanipulated haplo-HSCT, is remarkable in such a cohort of adult patients, with a median age of 51, an age usually characterized by a low thymic output. Immunological monitoring of transplanted patients shows that TK cells persist for up to 14 years after infusion (Oliveira et al., unpublished observation). The possibility to trace TK cells in treated patients offers a unique opportunity to investigate the fate of memory T cells in vivo.
Overall, the TK experience has been instrumental to validate the feasibility safety and efficacy of T cell-based gene therapy. To date, 148 patients have been treated with TK cells in several phase I-II clinical trials 23, [25] [26] [27] [28] [29] [30] [31] [32] worldwide, thus demonstrating the feasibility of this gene therapy approach. With a cumulative follow-up of more than 284 person/year, TK gene therapy proved to be safe, with no documented adverse event related to the gene transfer procedure. Accordingly, no genotoxic effect of integrating vectors, nor clonal dominance of gene modified T cells has been observed. 33 The TK approach is currently tested in a multicenter, randomized phase III clinical trial (TK008, NCT00914628) in Europe and in the United States. This is one of the first, and probably the TK008: study design largest cell-based gene therapy phase III trial. The trial design is shown in Figure 1 .
UNMANIPULATED PERIPHERAL BLOOD GRAFT AND SIROLIMUS-BASED GVHD PROPHYLAXIS
The profound TCD provided by ex vivo cell selection proved to be effective in preventing GvHD in haplo-HSCT 34, 35 and leukemia-free survival obtained in patients with high-risk acute leukemia in remission was comparable to outcomes obtained from matched unrelated donor and Umbilical Cord Blood (UCB) HSCT. 36, 37 Cell-based strategies aimed at improving post transplantation immune recovery showed a beneficial impact in abating infectious mortality 27 but in patients transplanted with advanced disease the high incidence of leukemia relapse still translated into a dismal clinical outcome. 36 In the peculiar clinical setting of patients with advanced leukemia, in 2007 we started exploring a GvHD prophylaxis regimen based on sirolimus and a graft based on G-CSF mobilized unmanipulated PBSCs. In that period, novel regimen of pharmacological immune suppression, such as the use of high-dose post transplantation CY, enabled the infusion of T cells harvested from the bone marrow of haploidentical donors with an acceptable incidence of GvHD, [38] [39] [40] [41] although no experience on PBSC was reported.
Sirolimus preferentially inhibits effector T cells, resulting in the relative expansion of natural T regulatory lymphocytes (Tregs). 42 Being endowed with suppressive activity not requiring previous antigen exposure, 43 natural Tregs are potential candidates for in vivo immune modulation in transplantation. The infusion of Tregs after UCB and haploidentical HSCT to prevent GvHD has produced promising results. 44, 45 Besides their effects on Tregs, sirolimus and analogs exert a direct antitumor activity against many malignancies. 46 In our Institute, we initially investigated Tregs clinical application by infusing haploidentical donor T lymphocytes pretreated with IL-10 (ALT-TEN trial, IS/11/6172/ 8309/8391). IL-10-anergized donor T cells (IL-10-DLI) contained T regulatory type 1 (Tr1) cells specific for the host alloantigens. IL-10-DLI was infused in 12 patients to improve immune reconstitution after haplo-HSCT without increasing the risk of GvHD. IL-10-DLI led to fast immune reconstitution in five patients; a transient GvHD was observed despite persistent host-specific hypo-responsiveness of donor T cells in vitro and enrichment of cells with Tr1-specific biomarkers in vivo. Gene-expression profiles of IR patients showed a common signature of tolerance. 47 In a clinical trial (TrRaMM protocol, Eudract 2007-5477-54), 19 we investigated the feasibility of unmanipulated mobilized haploidentical PBSC transplantation in patients affected by highrisk hematological malignancies, exploring as GvHD prophylaxis the association of sirolimus, mycophenolate mofetil (MMF), and anti-thymocyte globulin fresenius.
Patients received myeloablative conditioning based on Treosulfan 14 g/m 2 days − 6 through − 4 and Fludarabine 30 mg/m 2 days − 6 through − 2. GvHD prophylaxis was based on in vivo TCD by anti-thymocyte globulin fresenius (10 mg/kg) on days − 4 through − 2; sirolimus (orally, monitored twice a week to achieve a target plasma level of 8-15 ng/ml) from day − 1 and MMF (15 mg/kg tid orally or i.v.) from day 0. In the absence of aGvHD or disease relapse, sirolimus and MMF were tapered to discontinuation at 3 months and at 1 month after HSCT, respectively. Rituximab was administered in a single 500 mg dose on day − 1, as secondary prophylaxis of EBV reactivation and as an additional agent to deplete B cells in vivo and potentially reduce the incidence of cGvHD.
Donor PBSCs were mobilized with G-CSF and infused without any ex vivo manipulation, to achieve a target stem cell dose of 4-10 × 10 6 CD34 + cells/kg of patient body weight. Median CD34 + and CD3 + cell doses were 7.3 × 10 6 /kg (range 2.1-11.6) and 3.0 × 10 8 /kg (range 1.0-8.0), respectively. Neutrophil and platelet engraftment was fast and 98/104 patients (94%) presented donor chimerism equal to or above 95% at day 30 after HSCT. Patients achieved rapid immune reconstitution, showing at day 30 after HSCT median cell counts of 294 T cells/μL (range 4-2146) and 114 NK cells/μL (range 2-1404). MMF and sirolimus were continued for a median of 37 days (range 10-200) and 111 days (range 10-553), respectively. Cumulative incidence of grade II-IV aGvHD was 35 ± 9% at day 150 after HSCT. Cumulative incidence of grade III-IV aGvHD at day 150 after HSCT was 22 ± 8%. According to the revised Seattle criteria, 43 patients were diagnosed with cGvHD (13 limited and 30 extensive), accounting for an overall cumulative incidence of 47 ± 11% at 2 years. Overall, in the TrRaMM trial, the infusion of the unmanipulated haploidentical PBSC graft translated in a rate of GvHD that paralleled the observations in MUD based on PBSC graft and a standard calcineurin inhibitor-based GvHD prophylaxis.
At day 30 natural Tregs, identified as CD4
IL-7Ralpha − cells, represented on average 9.9% (range: 0.2-37.2%) of circulating CD4 + T cells, a percentage significantly higher than that observed in healthy subjects (P = 0.0026). Early Treg expansion was confirmed by molecular quantification of Foxp3 Treg-specific demethylated region. Interestingly, patients who experienced grade 0-I aGvHD had higher frequencies of circulating Tregs at day 30 after HSCT, as compared with those experiencing grade II aGvHD or severe aGvHD. Treg levels subsided upon sirolimus tapering, suggesting that the effect was dependent on drug administration.
OS and PFS at 1 year were 47 ± 8% and 34 ± 8%, respectively. TRM at 1 and 3 years after HSCT were 30 ± 8% and 31 ± 8% in a difficult patient population. Notably, we documented a considerable proportion of long-term survivors even among patients transplanted in presence of active leukemia or who had relapsed after a previous allogeneic transplant, the population that had been intentionally targeted in this exploratory trial.
Relapse incidence was as expected for such patients' population: 36 ± 9% at 1 year after HSCT and 48 ± 9% at 3 years. In patients with AML, we collected 33 leukemia relapses: interestingly 9 (27% of relapses) occurred in extramedullary sites and 11 (33% of relapses) were due to immune escape leukemic variants characterized by selective genomic loss of the HLA haplotype mismatched between patient and donor. 18 We analyzed the timing of different pattern of leukemia relapse and observed that relapse with loss of mismatched HLA occurred at a median of 375 days after HSCT, extramedullary relapses at a median of 205 days, and 'classical' bone marrow relapses at a median of 65 days after HSCT.
Despite PFS results comparable to matched related siblings and unrelated donors, 48 relapse still remained a major challenge for this group of patients with advanced disease. The low toxicity profile recorded in the TrRaMM trial, associated with the effective prevention of severe GvHD after infusion of large numbers of donor T cells within the PBSC graft, supported two major modifications: first, we implemented an intensification of conditioning with the addition of melphalan to myeloablative doses of treosulfan; second, based on previous studies on the feasibility and low toxicity profile of haplo-HSCT with high-dose PT-Cy (post transplant Cy), we planned to intensify this protocol for patients with active disease by the use of PT-Cy instead of anti-thymocyte globulin.
Since late 2012, 18 patients, 13 of which not in remission at the time of HSCT and scoring high/very high according to the CIBMTR disease score, 48 were treated with a conditioning regimen consisting of treosulfan (14 g/m 2 /day) on days -6 to -4, fludarabine (30 mg/m 2 /day) on days -6 to -2, and melphalan (70 mg/m 2 /day) on days -2 and -1, followed by T-repleted PBSCs from haploidentical donors. Postgrafting immunosuppression consisted of PT-Cy (50 mg/kg/day) on days 3 and 4, followed by MMF for 30 days, and sirolimus for 3 months. Preliminary results in these first patients indicate a safe tolerability of such regimen in advanced patients with a TRM of 11% at 100 days and a rate of grade III-IV acute GvHD of 22%. Post-HSCT recovery of lymphocyte subsets was broad and fast: the median CD3 count at day 30 after HSCT was 642/μL and exceeded 1000/μL by day 60, with a median value of CD4 T cell counts of 329/μL at day 30. Chronic GVHD occurred in 25% of patients at risk, but only one patient is long term on systemic therapy. 49 If confirmed in a larger cohort of patients and with a longer follow-up, these results suggest that the acceptable rates of GvHD and NRM as well as the favorable immune reconstitution profile open the way for combining it with novel immunomodulatory or cellular therapies to improve leukemia-free survival.
CONCLUSION AND FUTURE PERSPECTIVES
During the past decades, haplo-HSCT has become a tangible opportunity to treat patients affected by high-risk hematological malignancies, lacking an HLA-identical donor. In this setting, the immunological disparity between donor and host represents a double-edge sword: on one hand, it complicates the transplant procedure, increasing the risks of rejection, infections, and GvHD; on the other hand, it offers a unique opportunity to understand and ultimately redirect alloreactivity to malignant cells. In this review, we summarized the strategies implemented in our Institute with ultimate aim of translating haplo-HSCT into a multifaceted and personalized therapeutic approach. We envisage that this process will be rapidly enriched by the implementation of innovative cellular therapy products, currently under clinical development, such as TCR gene edited T cells, 50 and CAR redirected T cells. 51 
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